Hepatitis B virus (HBV) reactivation represents an emerging cause of liver disease in patients undergoing treatment with biologic agents. In particular, the risk of HBV reactivation is heightened by the use monoclonal antibodies, such as rituximab (anti-CD20) and alemtuzumab (anti-CD52) that cause profound and long-lasting immunosuppression. Emerging data indicate that HBV reactivation could also develop following the use of other biologic agents, such as tumor necrosis factor (TNF)-alpha inhibitors. When HBV reactivation is diagnosed, it is mandatory to suspend biologic treatment and start antiviral agents immediately. However, pre-emptive antiviral therapy prior to monoclonal antibody administration is crucial in preventing HBV reactivation and its clinical consequences. Several lines of evidence have shown that risk of HBV reactivation is greatly reduced by the identification of high-risk patients and the use of prophylactic antiviral therapy. In this article, we discuss current trends in the management of HBV reactivation in immunosuppressed patients receiving biologic therapy, such as rituximab, alemtuzumab and TNF-alpha antagonists. (C) 2011 Baishideng. All rights reserved.

Current trends in management of hepatitis B virus reactivation in the biologic therapy era / Mastroianni, Claudio Maria; Lichtner, Miriam; Rita, Citton; Cosmo Del, Borgo; Angela, Rago; Martini, Helene; Cimino, Giuseppe; Vullo, Vincenzo. - In: WORLD JOURNAL OF GASTROENTEROLOGY. - ISSN 1007-9327. - ELETTRONICO. - 17:34(2011), pp. 3881-3887. [10.3748/wjg.v17.i34.3881]

Current trends in management of hepatitis B virus reactivation in the biologic therapy era

MASTROIANNI, Claudio Maria;LICHTNER, Miriam;MARTINI, HELENE;CIMINO, Giuseppe;VULLO, Vincenzo
2011

Abstract

Hepatitis B virus (HBV) reactivation represents an emerging cause of liver disease in patients undergoing treatment with biologic agents. In particular, the risk of HBV reactivation is heightened by the use monoclonal antibodies, such as rituximab (anti-CD20) and alemtuzumab (anti-CD52) that cause profound and long-lasting immunosuppression. Emerging data indicate that HBV reactivation could also develop following the use of other biologic agents, such as tumor necrosis factor (TNF)-alpha inhibitors. When HBV reactivation is diagnosed, it is mandatory to suspend biologic treatment and start antiviral agents immediately. However, pre-emptive antiviral therapy prior to monoclonal antibody administration is crucial in preventing HBV reactivation and its clinical consequences. Several lines of evidence have shown that risk of HBV reactivation is greatly reduced by the identification of high-risk patients and the use of prophylactic antiviral therapy. In this article, we discuss current trends in the management of HBV reactivation in immunosuppressed patients receiving biologic therapy, such as rituximab, alemtuzumab and TNF-alpha antagonists. (C) 2011 Baishideng. All rights reserved.
antagonists; antiviral drugs; biologic agents; hepatitis b virus; rituximab; tumor necrosis factor-alpha antagonists; tumor necrosis factor-α; virus reactivation
01 Pubblicazione su rivista::01a Articolo in rivista
Current trends in management of hepatitis B virus reactivation in the biologic therapy era / Mastroianni, Claudio Maria; Lichtner, Miriam; Rita, Citton; Cosmo Del, Borgo; Angela, Rago; Martini, Helene; Cimino, Giuseppe; Vullo, Vincenzo. - In: WORLD JOURNAL OF GASTROENTEROLOGY. - ISSN 1007-9327. - ELETTRONICO. - 17:34(2011), pp. 3881-3887. [10.3748/wjg.v17.i34.3881]
File allegati a questo prodotto
File Dimensione Formato  
8_Mastroianni_punt88.pdf

solo gestori archivio

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 774.8 kB
Formato Adobe PDF
774.8 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/425633
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 49
  • ???jsp.display-item.citation.isi??? 49
social impact